The Study of Cost-Effectiveness of Rivaroxaban versus Warfarin in Patients with Atrial Fibrillation Who Developed Ischemic Stroke

INTRODUCTION: Rivaroxaban is a new anticoagulant providing benefits for the treatment of patients with atrial fibrillation (AF). This study is aimed at evaluating the cost-effectiveness of rivaroxaban compared to warfarin in patients with AF. METHOD: This economic evaluation study was conducted amon...

Descripción completa

Detalles Bibliográficos
Autores principales: Jaberi, Neda, Kavosi, Zahra, Hooshmandi, Etrat, Moradi, Nasrin, Keshavarz, Khosro, Borhani-Haghighi, Afshin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440110/
https://www.ncbi.nlm.nih.gov/pubmed/34531970
http://dx.doi.org/10.1155/2021/5534873

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440110/
https://www.ncbi.nlm.nih.gov/pubmed/34531970
http://dx.doi.org/10.1155/2021/5534873

Ejemplares similares